You are here

NHS spends almost 50% less on cancer drugs as some other EU countries

sandy craine's picture
Submitted by sandy craine on Fri, 23/05/2008 - 2:08pm
Britain's health service is spending half as much on cancer drugs as some other European countries April 2008 Speaking at the European Breast Cancer Conference in Berlin, Professor Mike Richards, the national cancer director, said that the Health Service is spending around half as much per head on cancer drugs as some other European countries. Figures showed Britain spent £76 per head in a year compared with £143 in Germany and £121 in France.

Britain's health service is spending half as much on cancer drugs as some other European countries

April 2008
Speaking at the European Breast Cancer Conference in Berlin, Professor Mike Richards, the national cancer director, said that the Health Service is spending around half as much per head on cancer drugs as some other European countries. Figures showed Britain spent £76 per head in a year compared with £143 in Germany and £121 in France.

CML Therapy: Making History, Making Progress. LLS interviews Brian J. Druker MD. March 2008

sandy craine's picture
Submitted by sandy craine on Mon, 19/05/2008 - 12:31pm
Brian Druker's original research into developing a way of blocking the protein (BCR/ABL) that drives CML, culminated in the development of a Tyrosine Kinase Inhibitor... namely Glivec/imatinib.

Brian Druker's original research into developing a way of blocking the protein (BCR/ABL) that drives CML, culminated in the development of a Tyrosine Kinase Inhibitor... namely Glivec/imatinib.

New Techniques Enabling a Greater Understanding of the Science and Biology of Leukemia: Interview With Dr. Brian Druker

sandy craine's picture
Submitted by sandy craine on Sun, 27/04/2008 - 7:12pm
Medscape Hematology-Oncology More: American Society of Hematology (ASH) 49th Annual Meeting and Exposition New Techniques Enabling a Greater Understanding of the Science and Biology of Leukemia: An Expert Interview With Dr. Brian Druker

Medscape Hematology-Oncology
More: American Society of Hematology (ASH) 49th Annual Meeting and Exposition
New Techniques Enabling a Greater Understanding of the Science and Biology of Leukemia:
An Expert Interview With Dr. Brian Druker

Medical News Today report that SGX393 is effective against Gleevec-resistant chronic myeloid leukemia (CML).

sandy craine's picture
Submitted by sandy craine on Thu, 27/03/2008 - 11:25am
New Research Gives Additional Therapeutic Tools For Even More Effective And Longer Control Of Chronic Myeloid Leukemia Main Category: Lymphoma / Leukemia Article Date: 25 Mar 2008 Oregon Health & Science University Cancer Institute researchers have found that an experimental drug known as SGX393 is effective against Gleevec-resistant chronic myeloid leukemia (CML). The results of their study will be published the week of March 24th in the Proceedings of the National Academy of Sciences.

New Research Gives Additional Therapeutic Tools For Even More Effective And Longer Control Of Chronic Myeloid Leukemia
Main Category: Lymphoma / Leukemia
Article Date: 25 Mar 2008

Oregon Health & Science University Cancer Institute researchers have found that an experimental drug known as SGX393 is effective against Gleevec-resistant chronic myeloid leukemia (CML). The results of their study will be published the week of March 24th in the Proceedings of the National Academy of Sciences.

Targeted Therapy in Chronic Myeloid Leukemia

sandy craine's picture
Submitted by sandy craine on Sat, 16/02/2008 - 1:47pm
02/06/2008 Elias Jabbour; Jorge E Cortes; Hady Ghanem; Susan O'Brien; Hagop M Kantarjian Abstract Chronic myeloid leukemia (CML) is characterized by the formation of the Philadelphia chromosome and oncogenic signaling by the resulting Bcr-Abl fusion protein. Understanding the molecular basis of CML has led to the development of highly effective targeted therapies that block Bcr-Abl tyrosine kinase activity. Imatinib, the current first-line therapy for CML, induces durable treatment responses in most patients. However, patients may develop imatinib resistance, which is often due to BCR-ABL mutations. With the availability of second generation tyrosine kinase inhibitors, an effective therapeutic option other than stem cell transplantation is available following imatinib failure. Randomized trial data suggest that dasatinib treatment is superior to imatinib dose escalation in patients with imatinib resistance. Nilotinib, a recently approved analogue of imatinib, has also demonstrated encouraging treatment responses in patients with imatinib-resistant CML. Other agents (including bosutinib and INNO-406) are in clinical development. With the potential availability of multiple treatment options for patients with CML, it may be possible to tailor treatment according to individual patient or disease characteristics, for example, BCR-ABL mutations. Future CML treatment may involve combination strategies. Overall, targeted agents have significantly improved the prognosis of patients diagnosed with CML.


02/06/2008

Elias Jabbour; Jorge E Cortes; Hady Ghanem; Susan O'Brien; Hagop M Kantarjian

Abstract
Chronic myeloid leukemia (CML) is characterized by the formation of the Philadelphia chromosome and oncogenic signaling by the resulting Bcr-Abl fusion protein. Understanding the molecular basis of CML has led to the development of highly effective targeted therapies that block Bcr-Abl tyrosine kinase activity. Imatinib, the current first-line therapy for CML, induces durable treatment responses in most patients. However, patients may develop imatinib resistance, which is often due to BCR-ABL mutations. With the availability of second generation tyrosine kinase inhibitors, an effective therapeutic option other than stem cell transplantation is available following imatinib failure. Randomized trial data suggest that dasatinib treatment is superior to imatinib dose escalation in patients with imatinib resistance. Nilotinib, a recently approved analogue of imatinib, has also demonstrated encouraging treatment responses in patients with imatinib-resistant CML. Other agents (including bosutinib and INNO-406) are in clinical development. With the potential availability of multiple treatment options for patients with CML, it may be possible to tailor treatment according to individual patient or disease characteristics, for example, BCR-ABL mutations. Future CML treatment may involve combination strategies. Overall, targeted agents have significantly improved the prognosis of patients diagnosed with CML.

Pages